ParaZero Files 424B5 Prospectus, Signals Potential Capital Raise

TL;DR

**ParaZero just filed a 424B5, likely gearing up to sell more stock, watch for dilution!**

AI Summary

ParaZero Technologies Ltd. filed a 424B5 prospectus on March 24, 2026, indicating a potential offering of securities under their existing shelf registration (File No. 333-281443). While the filing itself doesn't detail the specific terms like share count or price, it signals that ParaZero is preparing to raise capital. This matters to investors because any new issuance of shares could dilute the value of existing shares, potentially impacting the stock price, especially if the offering is large or priced below market value.

Why It Matters

This filing signals ParaZero's intent to potentially raise capital, which could dilute existing shareholders if new shares are issued, impacting the stock's value.

Risk Assessment

Risk Level: medium — The filing indicates a potential future offering, which carries the risk of dilution for current shareholders, but specific terms are not yet disclosed.

Analyst Insight

An investor should monitor ParaZero Technologies Ltd. for subsequent filings (like pricing supplements) that will detail the specific terms of any offering, as this will determine the extent of potential dilution and its impact on share price.

Key Players & Entities

• ParaZero Technologies Ltd. (company) — the filer of the 424B5 prospectus
• 0001916241 (person) — CIK of ParaZero Technologies Ltd.
• 333-281443 (person) — File number for ParaZero's shelf registration statement
• 2026-03-24 (person) — Filing date of the 424B5 prospectus

FAQ

Key Financial Figures

• $0.75 — rdinary Shares, at an offering price of $0.75 per Ordinary Share and (ii) pre-funded
• $0.74999 — Ordinary Shares at an offering price of $0.74999. Each registered pre-funded warrant wil
• $0.00001 — Ordinary Share at an exercise price of $0.00001 per Ordinary Share, will be immediately
• $1.07 — f our Ordinary Shares on the Nasdaq was $1.07. The highest aggregate market value of
• $31.1 million — n I.B.5. of Form F-3, was approximately $31.1 million. During the twelve calendar months imme
• $5,700,000 — supplement, we have sold approximately $5,700,000 of our securities pursuant to General I
• $50,000 — ent agent not to exceed an aggregate of $50,000. Please refer to the section entitled &
• $50 million — ime to time, sell up to an aggregate of $50 million of Ordinary Shares, warrants and units.
• $8.8 million — ch 20, 2026, we have sold approximately $8.8 million of our securities under that shelf regi
• $1.10 — ordinary shares at a purchase price of $1.10 per ordinary share and $1.09999 per pre
• $1.09999 — e price of $1.10 per ordinary share and $1.09999 per pre-funded warrant. The pre-funded
• $2.2 million — the August 2025 RDO were approximately $2.2 million. As of the date hereof, 200,000 pre-fu
• $100,000 — ugust 2025 RDO, we paid an aggregate of $100,000 in financial advisory fees. S-1 First
• $1.00 — ordinary shares at a purchase price of $1.00 per ordinary share and $0.99999 per pre
• $0.99999 — e price of $1.00 per ordinary share and $0.99999 per pre-funded warrant. The pre-funded

Filing Documents

• ea0282986-424b5_parazero.htm (424B5) — 364KB
• ea028298601_img1.jpg (GRAPHIC) — 12KB
• ea028298601_img2.jpg (GRAPHIC) — 12KB
• ea028298601_img3.jpg (GRAPHIC) — 12KB
• 0001213900-26-033215.txt ( ) — 415KB

RISK FACTORS

RISK FACTORS 3 NOTE REGARDING FORWARD-LOOKING 4 OFFER STATISTICS AND EXPECTED TIMETABLE 4 CAPITALIZATION 5

USE OF PROCEEDS

USE OF PROCEEDS 6 DESCRIPTION OF SHARE CAPITAL 7 DESCRIPTION OF WARRANTS 12 DESCRIPTION OF UNITS 13 PLAN OF DISTRIBUTION 14 LEGAL MATTERS 17 EXPERTS 17 EXPENSES 17 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 18 WHERE YOU CAN FIND ADDITIONAL INFORMATION 19 ENFORCEMENT OF CIVIL LIABILITIES 20 S-i ABOUT THIS PROSPECTUS SUPPLEMENT A registration statement on Form F-3 (File No. 333-281443) utilizing a shelf registration process relating to the securities described in this prospectus supplement was declared effective on August 16, 2024. Under that shelf registration statement, of which this prospectus supplement is a part, we may, from time to time, sell up to an aggregate of $50 million of Ordinary Shares, warrants and units. As of March 20, 2026, we have sold approximately $8.8 million of our securities under that shelf registration statement. We sometimes refer to the Ordinary Shares as the “securities” throughout this prospectus. This document contains two parts. The first part is this prospectus supplement, which describes the terms of this offering of the Ordinary Shares, and also adds, updates and changes information contained in the accompanying prospectus and the documents incorporated herein and therein by reference. The second part is the accompanying prospectus, which gives more general information about us, some of which may not apply to this offering. You should read both this prospectus supplement and the accompanying prospectus, including the information incorporated by reference herein and therein. To the extent the information contained in this prospectus supplement differs or varies from the information contained in the accompanying prospectus or any document filed prior to the date of this prospectus supplement and incorporated herein or therein by reference, the information in this prospectus supplement will control; provided, that if any statement in one of these documents is inconsistent with a

Use of proceeds

Use of proceeds We intend to use the net proceeds from the sale of securities under this prospectus for general corporate purposes and for working capital purposes. See “Use of Proceeds” on page S-12 of this prospectus supplement.

Risk factors

Risk factors Investing in the Ordinary Shares involves a high degree of risk. See “Risk Factors” beginning on page S-5 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of the risks you should carefully consider before deciding to invest in the Ordinary Shares. Nasdaq Capital Market symbol “PRZO” Unless otherwise stated, all information in this prospectus is based on 23,426,906 Ordinary Shares outstanding as of March 20, 2026, and does not include the following as of that date: up to 1,837,461 Ordinary Shares issuable upon the exercise of the Series A Warrants issued in our private placement in October 2023, or the October 2023 PIPE; warrants outstanding as of such date to purchase an aggregate of 353,367 Ordinary Shares at a weighted average exercise price of $3.16; 617,430 Ordinary Shares issuable upon the exercise of options under our incentive option plan, at a weighted average exercised price of $1.34, none of which were vested as of such date; and 1,474,381 restricted shares units outstanding that have not yet vested under our incentive option plan; and 2,446,071 Ordinary Shares reserved for future issuance under our incentive option plan. S-4

RISK FACTORS

RISK FACTORS Investing in our securities involves significant risks. Before making an investment decision, you should carefully consider the risks described below and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, together with all of the other information appearing in this prospectus supplement or the accompanying prospectus or incorporated by reference herein or therein, including in light of your particular investment objectives and financial circumstances. The risks so described are not the only risks we face. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations and become material. Our business, financial condition and results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. The discussion of risks includes or refers to forward-looking statements; you should read the explanation of the qualifications and limitations on such forward-looking

View Full Filing

View this 424B5 filing on SEC EDGAR